Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa

This study has been terminated.
(Enrollment never initiated, study withdrawn.)
Sponsor:
Collaborator:
United States Agency for International Development (USAID)
Information provided by:
Boston University
ClinicalTrials.gov Identifier:
NCT00270725
First received: December 27, 2005
Last updated: March 29, 2011
Last verified: March 2011
History of Changes

December 27, 2005
March 29, 2011
July 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00270725 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa
The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS
The purpose of this study is to determine the impact of anti-HIV treatment on the work attendance of employed people in South Africa. The study will enroll participants from a large manufacturing and distribution firm in South Africa.

Little is known about the economic benefits of providing antiretroviral therapy (ART) for HIV infected patients in sub-Saharan Africa and other resource-limited areas. In South Africa, an increasing number of private sector firms are providing access to ART for their employees. One of the barriers to such action, however, is the lack of available information on the success of ART in restoring workers to full productivity, retaining skilled employees in the workforce, and reducing the costs of medical care and death and disability benefits. HIV infected employees on ART may be absent from work less often than untreated HIV infected employees, but more often than HIV uninfected employees. This study will collect data from an independent HIV/AIDS disease treatment program and a large private sector employer in Johannesburg, South Africa to estimate the benefits and costs for businesses to provide ART to eligible employees.

The study will combine individual-level medical outcome and treatment cost data from the treatment program with data on employee work attendance and retention in the workforce from the participating employer. The work attendance of HIV infected employees enrolled in the HIV/AIDS treatment program (index participants) who are either taking ART or receiving pre-ART care will be compared with each other and with that of HIV uninfected employees. There are no study visits associated with this study; all data will be collected from medical records maintained by the HIV/AIDS treatment program and the participants' employer. The financial costs and benefits of the treatment program for the participating company will also be estimated.
Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample
see elig
HIV Infections
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
120
July 2005
Not Provided

Inclusion Criteria for All Participants:

  • Employed by participating company for at least 1 year prior to study entry

Inclusion Criteria for Index Participants:

  • Enrolled in the HIV/AIDS treatment program offered by the participating company

Exclusion Criteria for Index Participants:

  • Enrolled in the HIV/AIDS treatment program prior to 01/01/04 or after 06/30/05
Both
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
South Africa
 
NCT00270725
RTC-BU-01
Not Provided
Not Provided
Not Provided
Sydney Rosen, Boston University
Boston University
United States Agency for International Development (USAID)
Principal Investigator: Sydney B. Rosen, MPA Boston University
Boston University
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP